Dalia Cohen Ph.D. Joins Asterand as Chief Scientific Officer
September 22 2010 - 9:00AM
Business Wire
Asterand plc (LSE: ATD), a leading provider of human tissue and
human tissue-based research services to pharmaceutical and
biotechnology companies engaged in drug discovery research, today
announces the appointment of Dalia Cohen Ph.D. as Asterand’s Chief
Scientific Officer.
Dr. Cohen will have global responsibility for shaping and
leading the Company’s scientific positioning and strategy. Dr.
Cohen joins Asterand from Rosetta Genomics, a leading developer of
microRNA-based molecular diagnostics, where she currently serves as
Chief Scientific Officer. Dr. Cohen has fifteen years experience
working in several executive positions at Novartis Pharmaceuticals,
including: VP and Global Head for Strategic Enabling Technologies
and VP and Global Head of Functional Genomics.
Asterand’s CEO, Martyn Coombs, commented:
“We are delighted that Dr. Cohen has decided to join us. This
appointment is a clear symbol of Asterand’s ambition. Dr. Cohen is
a recognised name and leader in our field, and has a reputation as
an innovative scientist with an in-depth knowledge of drug
discovery and development, oncology, personalised medicine and
diagnostics. She is extremely well connected amongst the
pharmaceutical community and academia. Asterand now has twenty
Ph.Ds, and with Dr. Cohen leading our science, we believe that she
can help us move our company to the next level, and help us better
serve our customers.”
Asterand’s CSO, Dalia Cohen, noted:
“I’m delighted to join this talented management team.
Pharmaceutical and diagnostic companies are using human based
methods in research, and I believe that this will increase
dramatically in future years. Asterand has built a unique and
strong position in human biospecimen quality and breadth, and in
PhaseZERO services. In addition, through the acquisition of
BioSeek, Asterand has added the possibility of using sophisticated
human primary cell based models and screening to predict at an
early stage whether compounds will work in patients. I’m eager to
direct Asterand’s scientific strategy to maximise its growth
potential over the long term.”
About ASTERAND
Asterand plc is a leading supplier of high quality human tissue
and tissue-based services. Our comprehensive approach to human
tissue and research services offers pharmaceutical, biotech and
diagnostic companies the unique opportunity to have one company
meet all of their human biomaterial needs along the continuum of
drug discovery and development. Our mission is to accelerate target
discovery and compound validation and enable pharmaceutical and
biotechnology companies to take safer and more effective drugs into
the market. For more information about Asterand go to
www.asterand.com.
Bioseek (LSE:ATD)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bioseek (LSE:ATD)
Historical Stock Chart
From Nov 2023 to Nov 2024
